LPTX vs. AFMD, LFVN, CMRX, QTTB, ALRN, IFRX, ONCY, ETON, MRNS, and RVPH
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Affimed (AFMD), LifeVantage (LFVN), Chimerix (CMRX), Q32 Bio (QTTB), Aileron Therapeutics (ALRN), InflaRx (IFRX), Oncolytics Biotech (ONCY), Eton Pharmaceuticals (ETON), Marinus Pharmaceuticals (MRNS), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
Affimed received 141 more outperform votes than Leap Therapeutics when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 68.65% of users gave Leap Therapeutics an outperform vote.
Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -1,280.27%. Leap Therapeutics' return on equity of -118.17% beat Affimed's return on equity.
Affimed currently has a consensus target price of $45.00, indicating a potential upside of 730.26%. Leap Therapeutics has a consensus target price of $11.38, indicating a potential upside of 256.58%. Given Leap Therapeutics' higher probable upside, equities research analysts clearly believe Affimed is more favorable than Leap Therapeutics.
In the previous week, Affimed and Affimed both had 1 articles in the media. Leap Therapeutics' average media sentiment score of 1.91 beat Affimed's score of 0.00 indicating that Affimed is being referred to more favorably in the media.
Affimed has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
30.8% of Affimed shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Leap Therapeutics has lower revenue, but higher earnings than Affimed. Affimed is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Affimed beats Leap Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
